Physiological lentiviral vectors for the generation of improved CAR-T cells

Mostrar otras versiones (1)

Anti-CD19 chimeric antigen receptor (CAR)-T cells have achieved impressive outcomes for the treatment of relapsed and refractory B-lineage neoplasms. However, important limitations still remain due to severe adverse events (i.e., cytokine release syndrome and neuroinflammation) and relapse of 40%–50...

Descripción completa

Detalles Bibliográficos
Autores principales: Tristán-Manzano, María, Maldonado-Pérez, Noelia, Justicia-Lirio, Pedro, Muñoz, Pilar, Cortijo-Gutiérrez, Marina, Pavlovic, Kristina, Jiménez-Moreno, Rosario, Nogueras, Sonia, Carmona, M. Dolores, Sánchez-Hernández, Sabina, Aguilar-González, Araceli, Castella, María, Juan, Manel, Marañón, Concepción, Marchal, Juan Antonio, Benabdellah, Karim, Herrera, Concha, Martin, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163403/
https://www.ncbi.nlm.nih.gov/pubmed/35694446
http://dx.doi.org/10.1016/j.omto.2022.05.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163403/
https://www.ncbi.nlm.nih.gov/pubmed/35694446
http://dx.doi.org/10.1016/j.omto.2022.05.003

Ejemplares similares